Search results with tag "Hepatocellular carcinoma"
HIGHLIGHTS OF PRESCRIBING INFORMATION
www.lenvima.comHepatocellular Carcinoma (HCC) • For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). (1.3) Endometrial Carcinoma (EC) • In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is not microsatellite
Subclassification of BCLC B Stage Hepatocellular Carcinoma ...
www.med.kindai.ac.jpEuropean Organization for Research and Treatment of Cancer [2] . However, the concept of intermediate-stage HCC is absent from the Japanese Evidence-based Clini-cal Practice Guidelines for Hepatocellular Carcinoma [3], the Consensus-based Clinical Practice Guideline for the Management of Hepatocellular Carcinoma [4, 5] and
Nek2 augments sorafenib resistance by regulating the ...
jeccr.biomedcentral.comlocalization of β-catenin in hepatocellular carcinoma Ling Deng1, Jingyuan Sun1, Xiaohui Chen1, Li Liu2* and Dehua Wu1* Abstract Background: Sorafenib is the first-line treatment for advanced-stage hepatocellular carcinoma (HCC). Several studies have shown that the up-regulation of β-catenin plays a role in sorafenib resistance in HCC ...
YERVOY U.S. Prescribing Information
packageinserts.bms.comHepatocellular Carcinoma • Treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib, in combination with nivolumab. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon ...
Diagnosis, Staging, and Management of Hepatocellular ...
www.aasld.orgHepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases Jorge a. Marrero,1 laura M. Kulik,2 Claude B. Sirlin,3 andrew X. Zhu,4 Richard S. Finn,5 Michael M. abecassis,2 lewis R. Roberts,6 and Julie K. Heimbach6 Purpose and Scope This guidance provides a data-supported approach
Modified RECIST (mRECIST) Assessment for Hepatocellular ...
imaging.cancer.govMeasurement of response rate in hepatocellular carcinoma (HCC) has become a con-troversialissue.TheWorld Health Organization (WHO)criteria underestimate the actual response rate; thus, they were amended in 2000 by a panel of experts convened by the European Association for the Study of the Liver (EASL) to take into account treatment-
ACG Clinical Guideline: Diagnosis and Management of Focal ...
acgcdn.gi.orgthe evaluation of liver lesions has taken on greater importance because of the increasing incidence of primary hepatic malignancies, especially hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Therefore, a thorough and systematic approach to the management of focal liver lesions (FLLs) is of utmost importance.
Protocol for the Examination of Specimens From Patients ...
www.cap.orgGastrointestinal • Hepatocellular Carcinoma . Hepatocellular 4.0.0.0 . Accreditation Requirements . This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes.
Hepatitis B: Diagnosis and Treatment - American Academy …
www.aafp.orgApr 15, 2010 · hepatocellular carcinoma.1,2 Approximately 88 percent of the world’s population live in regions where the prevalence of chronic HBV infection among adults is more than 2 per-
EASL 2017 Clinical Practice Guidelines on the management ...
www.hepb.orgEuropean Association for the Study of the Liver ... are at increased risk of progression to cirrhosis and hepatocellular carcinoma (HCC), depending on host and viral factors. The main goal of therapy is to improve survival and quality of life by pre-
Diagnosis and management of hemochromatosis: 2011 …
www.aasld.org2011 Practice Guideline by the American Association ... hepatocellular carcinoma (HCC), diabetes, and heart All AASLD Practice Guidelines are updated annually. If you are viewing a Practice Guideline that is more than 12 months old, please visit www.aasld.org for ... ence of the European Association for the Study of Liver Diseases in 2000.13 ...
EASL recommendations on treatment of hepatitis C: Final ...
easl.euEuropean Association for the Study of the Liver* Summary Hepatitis C virus (HCV) infection is a major cause of chronic liver ... fibrosis and cirrhosis with or without hepatocellular carcinoma (HCC). Clinical care for patients with HCV-related liver disease has advanced considerably during the last couple of decades,
HIGHLIGHTS OF PRESCRIBING INFORMATION Gastric Cancer ...
packageinserts.bms.com• Hepatocellular carcinoma • 1 mg/kg followed by ipilimumab 3 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2) • Adjuvant treatment of resected esophageal or gastroesophageal cancer
EASL–EORTC Clinical Practice Guidelines: Management of ...
www.easl.euEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver⇑, European Organisation for Research and Treatment of Cancer
Hepatocellular Carcinoma (Liver Cancer): Introduction
www.hopkinsmedicine.orgHepatocellular carcinoma is a tumor of the liver . Hepatocellular carcinoma is responsible for over 12,000 deaths per year in the United States where the incidence of the disease is approximately 2.5 per 100,000 population. It is one of the most common malignancies in adults, and is more common in men than women (2-4:1), and blacks than whites.
Similar queries
Hepatocellular carcinoma, Carcinoma, Treatment, Of Hepatocellular Carcinoma, YERVOY, Of Hepatocellular, Hepatocellular, Liver, Hepatitis B: Diagnosis and Treatment, European Association, Diagnosis and management of hemochromatosis, Association, EASL recommendations on treatment of hepatitis, Clinical Practice Guidelines